IRVINE, Calif., April 9, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the launch of two new products from SkinMedica® by the makers of BOTOX® Cosmetic. The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people with acne-prone skin. The two products, along with the SkinMedica® Pore Purifying Pro-Infusion Serum, used in-office with DiamondGlow®, complete the protocol, providing acne sufferers a continuum of products to help address their skin concerns.
"Acne is the most common skin concern in the US.1 It is also the primary reason patients schedule an office visit with their provider.2 For 25 years, SkinMedica® has been dedicated to perfecting scientifically proven skincare that yields visible results," said Jasson Gilmore, Senior Vice President, U.S. Aesthetics. "The formulations of the new products continue the legacy of promoting skin health and addressing key patient concerns like acne."
In clinical studies, participants who used the SkinMedica® Acne Clarifying Treatment and Pore Purifying Gel Cleanser noticed clearer skin while reporting that the products did not dry their skin out. Additionally, clinical study participants noted the treatment regimen helped calm their skin.3 The SkinMedica® approach to addressing acne focuses on efficacy while respecting the skin barrier to help break the acne cycle by balancing sebum, soothing visible redness, and preserving the microbiome.
"Navigating the challenges posed by acne can be difficult, and most acne products are effective at targeting acne but ignore the impact of the ingredients on the skin barrier," said Dr. Mona Gohara, board-certified dermatologist and associate clinical professor at Yale University. "My patients often find themselves in a bind when choosing acne products that treat acne but don't compromise the skin barrier. I am excited to offer my patients these new products from SkinMedica®, which focus on sebum regulation and barrier protection to create a desirable balance of low irritation with strong efficacy."
The SkinMedica® Acne Clarifying Treatment is formulated with 2% encapsulated salicylic acid, which proactively guards against future breakouts. The product also includes ingredients like niacinamide and bakuchiol, which work together to reduce the appearance of discoloration and post-acne marks while refining pores and enhancing skin tone. With each application, this treatment becomes a shield, preserving the skin's natural barrier. MSRP $66.
Complementing the Acne Clarifying Treatment is the SkinMedica® Pore Purifying Cleanser, which is infused with salicylic acid, a beta-hydroxy acid, to help remove impurities while a potent blend of antioxidants and soothing botanicals like aloe and chamomile caress the skin, leaving behind a soft and refreshed canvas. MSRP $46.
The new SkinMedica® products are available for purchase at SkinMedica.com and through a network of licensed physicians and medically supervised spas. To experience the SkinMedica® Pore Purifying Pro-Infusion Serum for DiamondGlow®, find a provider by visiting DiamondGlow.com. For more information follow @SkinMedica on Instagram.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
DiamondGlow® Uses
The DiamondGlow® device is a general dermabrasion device that gently removes the top layer of skin and delivers topical cosmetic serums onto the skin.
DiamondGlow® Important Safety Information
The DiamondGlow® treatment is not for everyone. You should not have a DiamondGlow® treatment if you have compromised skin quality. Tell your provider if you are pregnant or lactating, or if you have any medical conditions, including allergies, and if you are using topical medications on the area to be treated.
Typical side effects include a scratchy, stinging sensation during the treatment and temporary tightness, redness or slight swelling after the treatment. Rare serious side effects may also occur and include severe skin irritation and allergic reactions.
SkinMedica® Pro-Infusion Serums Disclaimer
SkinMedica® Pro-Infusion Serums are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These products are not intended to be drugs that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA.
Please talk to your provider for additional information.
SkinMedica® Important Information
Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA.
SkinMedica® Acne Clarifying Treatment is an over-the-counter drug product which is formulated and marketed pursuant to FDA's governing regulations set forth at 21 CFR Part 333 Subpart D.
For more information, please talk to your provider or visit SkinMedica.com and DiamondGlow.com. To report an adverse reaction, please call Allergan at 1-800-433-8871.
BOTOX® COSMETIC IMPORTANT SAFETY INFORMATION AND APPROVED USES
IMPORTANT SAFETY INFORMATION
BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:
BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, and/or forehead lines.
BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.
Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.
Do not receive BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.
Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of BOTOX® Cosmetic.
Tell your doctor about all your medical conditions, including: plans to have surgery; had surgery on your face; have trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past.
Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc®, Dysport®, or Xeomin® in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners.
Other side effects of BOTOX® Cosmetic include: dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of your eyelids and dry eyes.
Approved Uses
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.
For more information refer to the Medication Guide or talk with your doctor.
To report a side effect, please call Allergan at 1-800-678-1605.
Please see BOTOX® Cosmetic full Product Information including Boxed Warning and Medication Guide.
References:
| Last Trade: | US$166.59 |
| Daily Change: | 1.60 0.97 |
| Daily Volume: | 3,368,365 |
| Market Cap: | US$294.860B |
November 18, 2024 October 31, 2024 October 30, 2024 October 28, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
